• Ovid Therapeutics outlined a pipeline strategy focused on small-molecule medicines for conditions driven by neural hyperexcitability, with multiple clinical and regulatory milestones targeted across 2026-2027.
• Lead program OV329, a next-generation GABA-aminotransferase inhibitor, is slated to enter four proof-of-concept studies across focal onset seizures, tuberous sclerosis complex-associated seizures, and infantile spasms.
• Key milestones include Phase 2 initiation in Q2 2026, an open-label photosensitive epilepsy study using photo-paroxysmal response with initiation and results in H2 2026, Phase 2a topline results in mid-2027, and a pediatric signal-finding study expected to start in Q4 2026.
• Ovid highlighted Phase 1 data for OV329 showing dose-dependent cortical inhibition, no ophthalmic or retinal changes across tested doses, and modeling that targets adult focal onset seizure enzyme inhibition of about 50%-60% at modeled plasma exposure of about 60-120 ng hr/mL.
• Second program OV4071, an oral KCC2 direct activator aimed initially at psychosis associated with Parkinson’s disease and Lewy body dementia, is set for Phase 1 initiation in Q2 2026, with a ketamine proof-of-mechanism study planned for H2 2026 and Phase 1b proof-of-concept work spanning H2 2026-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.